All In Biotech

Drug Trial Radar · NCT00276068

Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine

Vulvar Vestibulitis Trial: Desipramine-Lidocaine

Last checked: Nov 20, 2026Latest source record: Nov 14, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

128

Planned (sponsor's estimate)

Start

Aug 2002

Primary completion

Not stated

Study completion Sep 2007

Sponsor

Lead sponsor
University of RochesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 12, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Vulvar Vestibulitis Clinical Trial (VVCT) a randomized, placebo-controlled, double blinded clinical trial. We will study the clinical efficacy of four medical treatments for vulvar vestibulitis: topical lidocaine, oral desipramine, combined lidocaine and desipramine, and placebo cream and capsules. Desipramine is a tricyclic antidepressant commonly used by clinicians for treatment of several chronic pain conditions that demonstrates an optimal side effect profile compared to other tricyclic antidepressants. Topical lidocaine has also been found to be beneficial for vulvar vestibulitis treatment in small studies. It is hypothesized that the combined use of oral desipramine and topical lidocaine will be more therapeutically effective than either one by itself and better than placebo.

Conditions

  • Vulvar Disease

Interventions

  • topical lidocaine + oral desipramine, and/or placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary outcome variable will compare the reported pain of the "Tampon Test" (mean of Weeks -2, -1, and 0), prior to randomization to the reported pain of "Tampon Test" (mean of Weeks 10, 11, and 12).Time frame: The dependent (primary outcome) variable will be defined as the percent change of mean "Tampon test" pain of Weeks (10, 11, and 12) from Weeks (-2, -1 and 0).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Strong Memorial Hospital

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.